NICE gives limited backing to Bayer's Xofigo; Merck KGaA criticizes NICE's Erbitux rejection in bowel cancer;

@FiercePharma: Zoetis ups the ante in prevention with new flu vaccine and flea fighter for dogs. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Baxalta Singapore plant gets FDA OK to produce Advate. Article | Follow @EricPFierce

> U.K. cost-effectiveness watchdogs gave limited backing to Bayer's prostate cancer therapy Xofigo, recommending it only in patients who've already undergone chemotherapy. Report

> Merck KGaA took issue with the National Institute for Health and Care Excellence's (NICE) decision not to recommend its drug Erbitux for previously untreated metastatic colorectal cancer. Report

> The FDA again rejected AMAG Pharmaceuticals' ($AMAG) single-dose version of its hormone injection Makena. Report

Medical Device News

@FierceMedDev: The top women in medical devices 2015. Feature | Follow @FierceMedDev

@VarunSaxena2: RetroSense bags $6M in funding for its viral vector gene therapy candidate for a rare eye condition. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Dx Digest: Invitae builds out cancer and epilepsy testing menus; Illumina gets in on autism research. More | Follow @EmilyWFierce

> Diabetes duodenal resurfacing startup Fractyl bumps Series C up to $57M. More

> Teva teams up with University College London for brain imaging study. Story

> Torax Medical earns key reimbursement code for its implant to treat gastric reflux. Article

Biotech News

@FierceBiotech: UCSD team targeting new stress pathway in Alzheimer's program. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: The Brent Saunders argument that he's opposed to R&D is a bit specious. $AGN acquires late-stage assets, avoids discovery. Not anti-research. | Follow @JohnCFierce

> KaloBios is back from the dead after Shkreli swoops in to 'save' its lead drug. Story

> Pfizer snags U.S. rights to Cellectis' white-hot CAR-T therapy. Article

> Silicon Valley VC shop Andreessen Horowitz sets up $200M bio fund. Report

CRO News

> WuXi lands a lead role in Genomics England's big project. Item

> Parexel touts its IT-enabled R&D services amid company shakeup. Report

> Fast-growing Charles River trades $36M for a drug discovery outfit. Article

> PRA expands in Singapore with eyes on Asian growth. Story

Pharma Manufacturing News

> Merck KGaA JV set to start producing drugs in remote Algerian village. More

> Shortages, shifts in sterile injectable market lead some prices to soar. Story

> Drug distributor recalls anxiety drug after wrong med found in a bottle. Report

> With pharma cargo theft on the rise, Thanksgiving can be a risky holiday. Item

> Hikma says FDA has closed out warning letter for EU injectables plant. Article

Pharma Asia News

> India's Supreme Court wants stricter oversight of MSD, GSK HPV clinical trials. More

> Price controls loom for generic drugs in India next year. Report

> Samsung Bioepis biosimilar may get nod in Europe. Story

> Mundipharma licenses Spectrum's NHL treatment, picks up Japan affiliate. Item

> GSK beefing up vaccine business in India. Article

And Finally... Presidential candidates have offered a variety of proposals to put a lid on drug-price hikes, but none seem likely to work very well, experts say. Report

Suggested Articles

If Pfizer wants Lorbrena to be a true follow-up to Xalkori, it has to win a first-line OK in ALK-positive lung cancer. And it just got closer.

Eylea sales dropped 4% to $1.11 billion amid the pandemic, but still beat expectations. And meanwhile, Regeneron's COVID antibody is advancing.

Johnson & Johnson inked a $10-per-dose vaccine supply deal with the U.S. for 100 million initial doses, with 200 million more available down the line.